Acciones AXIM Biotechnologies, Inc. Other OTC
Acciones
AXIM
US05463V1008
Biotecnología e investigación médica
Ventas 2022 | 8,88 mil 8,18 mil | Ventas 2023 | 39,52 mil 36,4 mil | Capitalización | 4,52 M 4,16 M |
---|---|---|---|---|---|
Resultado Neto 2022 | -6 M -5,53 M | Resultado Neto 2023 | -8 M -7,37 M | VE / Ventas 2022 | 1.218 x |
Deuda neta 2022 | 5,64 M 5,2 M | Deuda neta 2023 | 5,74 M 5,29 M | VE / Ventas 2023 | 259 x |
P/E ratio 2022 |
-0,69
x | P/E ratio 2023 |
-0,48
x | Empleados | - |
Rendimiento 2022 * |
-
| Rendimiento 2023 |
-
| Flotante | 74,42 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 29/06/16 |
Kurt Phinney
COO | Chief Operating Officer | - | 23/05/23 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 18/05/17 |
Director/Board Member | 76 | 18/05/17 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+40,80 % | 54,04 mil M | |
+43,57 % | 41,96 mil M | |
-1,15 % | 41,92 mil M | |
-7,59 % | 28,35 mil M | |
+12,54 % | 26,35 mil M | |
-22,12 % | 19 mil M | |
+7,76 % | 13 mil M | |
+28,66 % | 12,28 mil M | |
+24,89 % | 12,19 mil M |